Here are some key highlights:
- A clinical trial assessing the efficacy, safety, and tolerability of Tozorakimab (Anti-IL-33 mAb) in patients with moderate-to-severe COPD.
- Patients will receive close monitoring throughout the study.
- Participants are provided with a substantial stipend.
- All inhalers, including rescue inhalers, are fully covered for the duration of the study.
- Henry Ford also stands to receive a significant stipend for every patient who completes all study visits.
While this study presents a fantastic opportunity, recruiting eligible patients will be challenging due to its specific inclusion and exclusion criteria.
Please do not hesitate to forward the MRN of any symptomatic COPD patients on triple therapy who have been admitted OR have had two courses of steroids in the last year to our research coordinators Nicolas Ebner, Ruth George or Roel Almario.